Who to call at Celltrion, and when

Fundz watches for the moments Celltrion starts buying, and tells you who to reach.

An alert the day Celltrion raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Celltrion, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Celltrion. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Celltrion Secures Exclusive Supply Agreement for Omlyclo and Aptozma with U.S. Healthcare Company to Expand Market Access.

Oct 26, 2026

Contract Type

agreement

IncheonManufacturingBiotechnologyTherapeuticsPharmaceuticalBiopharma

Description

Celltrion has signed a significant exclusive supply agreement with a major U.S. healthcare company for its products Omlyclo and Aptozma. This agreement will ensure that both treatments are listed as preferred drugs on the insurer's formulary, aiming to enhance accessibility and insurance reimbursement for patients.

Company Information

Company

Celltrion

Location

Incheon, Seoul, South Korea

About

Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. The company’s solutions include world-class monoclonal antibody biosimilars such as Remsima®, Truxima® and Herzuma®, providing broader patient access globally. Celltrion has also received U.S. FDA and EC approval for several products, enhancing its portfolio in the biopharmaceutical industry.